| Name | N-(4-Chlorophenyl)-5,5-difluoro-1-[3-(4-pyridinyl)benzoyl]-3-piperidinecarboxamide |
|---|---|
| Synonyms |
3-Piperidinecarboxamide, N-(4-chlorophenyl)-5,5-difluoro-1-[3-(4-pyridinyl)benzoyl]-
N-(4-Chlorophenyl)-5,5-difluoro-1-[3-(4-pyridinyl)benzoyl]-3-piperidinecarboxamide |
| Description | CCG-232601 is a potent (IC50=0.55 uM), orally bioavailable Rho/MKL1/SRF transcriptional pathway that target transcriptional factor MRTF; inhibits the development of bleomycin-induced dermal fibrosis in mice when administered at 50mg/kg. |
|---|---|
| References | References 1. Hutchings KM, et al. Bioorg Med Chem Lett. 2017 Apr 15;27(8):1744-1749. View Related Products by Target Other Targets |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 683.1±55.0 °C at 760 mmHg |
| Molecular Formula | C24H20ClF2N3O2 |
| Molecular Weight | 455.884 |
| Flash Point | 366.9±31.5 °C |
| Exact Mass | 455.121216 |
| LogP | 3.10 |
| Vapour Pressure | 0.0±2.1 mmHg at 25°C |
| Index of Refraction | 1.636 |